HER2 Vaccine for Locally Advanced Breast Cancer

NCT ID: NCT06949410

Last Updated: 2025-12-26

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-03-31
• Study Completion Date: 2030-03-31

Brief Summary

The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.

Conditions

Breast Cancer; HER2-positive Breast Cancer

Keywords

vaccine; immune system; immunotherapy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

HER2 Vaccine Arm

MVF-HER2 266-296 and MVF HER2 597-626 peptide vaccines are combined in 1.5 mg doses of each peptide into a 3.0 mg total dose. This is administered intramuscularly in the gluteus maximus once every 21 days for three doses, in alternating sides (i.e. left-\>right-\>left), with a booster administered at 6 months.

Group Type: EXPERIMENTAL

HER2 Vaccine

Intervention Type: DRUG

MVF-HER2 266-296 and MVF HER2 597-626 peptide vaccines

Interventions

HER2 Vaccine

MVF-HER2 266-296 and MVF HER2 597-626 peptide vaccines

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. ≥ 18 years old at the time of informed consent

2. Ability to provide written informed consent and HIPAA authorization CTO-IUSCC-0864

3. Histologically confirmed HER2 positive breast cancer

1. Any Estrogen Receptor/Progesterone Receptor status is allowed.

2. HER2 positive is defined as HER2 3+ by immunohistochemistry (IHC) or 2+ by IHC associated with a fluorescence in situ hybridization (FISH) ratio of > 2.0 or > 6 total HER2 gene copies per cell.

4. High-risk disease defined as one of the following:

1. Any residual invasive carcinoma in the breast or axillary nodes in the final pathology from resected tumor following neoadjuvant taxane and trastuzumab-based chemotherapy

2. Inflammatory phenotype at the time of diagnosis per the treating physician

3. Clinical stage III disease at the time of diagnosis per the treating physician and/or clinical imaging

4. Locally recurrent disease and have undergone definitive local therapy

5. Received at least six months of HER2 targeted therapy with trastuzmab +/- pertuzumab TDM-1, or others in the neoadjuvant or adjuvant setting

a. Any combination of HER2 targeted therapy in the curative setting is allowed, including neratinib or others on a clinical trial

6. Completed last dose of HER2 targeted therapy no more than 6 months prior to registration

7. Completed last dose of cytotoxic chemotherapy or radiation at least 30 days prior to registration with resolution of any prior toxicity to ≤ 2 with the exception of alopecia

8. ECOG performance status of 0 to 2

9. Adequate organ function as indicated by:

1. Total bilirubin < 1.5 mg/dL (except in patients with documented Gilbert's disease, who must have a total bilirubin < 3.0 mg/dL)

2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.0 x ULN

3. Calculated creatinine clearance of > 60 mL/min using the Cockcroft-Gault formula

4. Absolute neutrophil count (ANC) > 1.0 K/mm3

5. Platelets > 100 K/ mm3

10. Adequate cardiac function defined as left ventricular ejection fraction (LVEF) above the institutional lower limit of normal by echocardiogram or MUGA obtained within 90 days of registration

11. Women of childbearing potential must have a negative serum pregnancy test within 14 days of protocol registration. Women are considered to have childbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) unless they meet one of the following criteria:

1. Has undergone a hysterectomy or bilateral oophorectomy; or

2. Has been naturally amenorrheic for at least 12 consecutive months.

12. Women of childbearing potential and men must agree to use one effective contraception throughout the study and for 6 months after the last study treatment.

Note: Acceptable methods of birth control include abstinence, partner with previous vasectomy, placement of an intrauterine device (IUD), condom with spermicidal foam/gel/film/cream/suppository, diaphragm or cervical vault cap, or hormonal birth control (pills or injections).

Exclusion Criteria

1. Any distant disease recurrence.

2. Patients with active malignancy other than breast cancer. Note: Patients with prior malignancies without recurrence after standard treatment will not be excluded.

3. Patients receiving or planned to receive adjuvant CDK4/6 inhibitor therapy

4. Patients who are {MVF-HER-2(266-296) and MVF-HER-2 (597-626)} immediate hypersensitivity skin test positive.

5. Patients who require or likely to require corticosteroids or other immunosuppressives

6. Patients with active autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis dermato-myositis, or a vasculitic syndrome.

Note: At the discretion of the treating physician, patients who show disease control for at least 6 months and do not require immunosuppressives may be enrolled.

7. Patients who have developed anaphylactic responses to other vaccines.

8. Patients who have evidence of active infection that requires antibiotic therapy. Patients must have been off antibiotic treatment for at least 3 weeks prior to initiating treatment and must be confirmed to be clear of the infection.

9. Known seropositive or active viral infection with human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV). Seropositivity due to vaccination are eligible.

10. Uncontrolled illness that would limit safety or compliance with study procedures including, but not limited to, active infection, congestive heart failure, unstable angina, or cardiac arrhythmia.

11. Patients with serious uncontrolled cardiopulmonary disorders, including congestive heart failure, symptomatic coronary artery disease, serious cardiac arrhythmia, and symptomatic chronic obstructive pulmonary disease or patients with other serious uncontrolled medical diseases. At the discretion of the treating physician, patients who show disease control for at least 6 months may be enrolled.

12. History of splenectomy

13. Pregnant or breast feeding.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pravin T.P Kaumaya

OTHER

Sponsor Role: lead

Responsible Party

Pravin T.P Kaumaya

The Vera Bradley Foundation Endowed Chair in Breast Cancer Innovation Professor of Microbiology & Immunology

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Pravin Kaumaya, PhD

Role: PRINCIPAL_INVESTIGATOR

Indiana University

Locations

Indiana University Melvin & Bren Simon Comprehensive Cancer Center

Indianapolis, Indiana, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Niraj Shah

Role: CONTACT

Phone: 317-278-3420

Email: shahnir@iu.edu

Facility Contacts

Niraj Shah

Role: primary

Other Identifiers

CTO-IUSCCC-0864

Identifier Type: -

Identifier Source: org_study_id